Poulseur (BE)
{name}
{subtitle}
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
city
~12 mi. (Liège, Belgium, +55 more cities)
facility
Centre Hospitalier Universitaire de Liège Site Sart Tilman (Adults and Pediatrics)
condition
Post-Transplant Lymphoproliferative Disorder
drug
tabelecleucel
drug type
cellular therapy, +1 more type
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~18 mi. (Verviers, Belgium, +176 more cities)
facility
CHR Verviers ( Site 2035)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~32 mi. (Maastricht, Netherlands, +192 more cities)
facility
Maastricht UMC+
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~32 mi. (Maastricht, Netherlands, +89 more cities)
facility
Maastricht UMC+-Medical Oncology ( Site 1353)
biomarker
ER Positive, +2 more biomarkers
condition
Breast Carcinoma
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~32 mi. (Maastricht, Netherlands, +226 more cities)
facility
Maastricht University Medical Centre ( Site 0467)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~32 mi. (Maastricht, Netherlands, +140 more cities)
facility
Maastricht University Medical Centre ( Site 0440)
condition
Hepatocellular Carcinoma
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~32 mi. (Maastricht, Netherlands, +130 more cities)
facility
Maastricht University Medical Centre ( Site 0453)
condition
Bladder Urothelial Carcinoma
drug
BCG solution, +1 more drug
drug type
immunotherapy